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It is now well established that severe mental illness (SMI) is associated with a reduced lifespan and
increased risk of cardiovascular disease (CVD). Individuals with SMI often have abnormalities of lipid
metabolism, glucose homeostasis, an increased prevalence of obesity and hypertension. They also have
an increased prevalence of Metabolic Syndrome (MetS). The reasons for this are not entirely clear, but are
likely to be multifactorial. Whilst there have been numerous studies investigating the prevalence of MetS
in patients with SMI, many have been in small, mixed population samples, that have not been adequately
controlled for the background population from which they have been drawn. This is important because
of the wide range of prevalence estimates that have been reported, and variations of MetS prevalence
with ethnicity. The negative impact of treatment with second-generation antipsychotic (SGA) drugs on
the risk of MetS also appears clear in most populations, although the mechanisms accounting for this
increased risk are yet to be clariﬁed. Despite this high prevalence of CVD risk factors in patients with SMI,
most studies report a poor implementation of screening for CVD risk factors at baseline, and following
initiation of treatment with SGAs. Not all patients with SMI are susceptible to the adverse effects of SGAs,
but in those that are, switching to an anti-psychotic that is less likely to cause metabolic disturbance,
starting statin therapy and a reduction in CVD risk factors through changes in lifestyle may all be
important strategies.
© 2018 KeAi Communications Co., Ltd. Publishing Services by Elsevier B.V. on behalf of KeAi
Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Severe mental illness (SMI) is associated with a substantially
reduced life expectancy.1,2 The complexity of deﬁning SMI has been
outlined by the Director of the US National Institute of Mental
Health,3 and in the United States (US) a practical and pragmatic
approach has been used4; SMI therefore comprises psychotic and
affective disorders that lead to functional impairment that affect
major life activities. The increased risk of premature cardiovascular
disease (CVD) in individuals with SMI is particularly notable, and
this has been attributed, in part, to a high prevalence of metabolic
syndrome (MetS). The latter condition, also termed Syndrome X bynications Co., Ltd.
vier on behalf of KeAi
lishing Services by Elsevier B.V. on
es/by-nc-nd/4.0/).
Cause, consequence or coinc
e Research (2018), https://doReaven,5 is characterised by a clustering of several CVD risk factors
that include central obesity, dyslipidaemia, hypertension and
impaired glucose tolerance. Reaven has argued that insulin resis-
tance (IR) is the central metabolic defect in MetS. Bjorntorp noted
that stress-related cortisol secretion is often enhanced in in-
dividuals with central obesity and that this may lead to IR and the
other features of MetS.6 His team further observed that the
hypothalamic-pituitary adrenal (HPA) axis may be stimulated by
several socio-economic and psychosocial factors, which include:
alcohol, smoking and traits of psychiatric disease.7 Therefore, the
relationship between major psychiatric conditions such as schizo-
phrenia and bipolar disorder (BD), and risk of MetS and cardio-
vascular disease (CVD) may be due to:
1) SMI being a cause of MetS, due to the direct effects of psychiatric
disease, or its treatment,8,9 on the metabolic and hormonal
milieu,10 or on patterns of behaviour that increase the risk of the
components of MetS;11,12
2) SMI being a consequence of the potential impact of the MetS,13
and particularly obesity,14 on mental wellbeing,15 orbehalf of KeAi Communications Co., Ltd. This is an open access article under the CC
idence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
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Treatment Panel-III
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AUD Alcohol use disorder
BD Bipolar disorder
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FES First episode schizophrenia
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HPA Hypopituitary-pituitary-adrenal
ICD International Classiﬁcation of Diseases
IDF-AHA/NHLBI International Diabetes Federation-American
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Blood Institute
IDF International Federation of Diabetes
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
IR Insulin-resistance
IS Insulin-sensitivity
JIS Joint Interim Statement
LDL-C Low-density lipoprotein-cholesterol
MDD Major depressive disorder
MI Myocardial infarction
MetS Metabolic Syndrome
MTHFR methylenetetrahydrofolate reductase
NHANES National Health and Nutrition Examination Survey
OR Odds ratio
PCOS Polycystic ovary syndrome
PHQ-9 Patient Health Questionnaire-9
PPARs Peroxisome Proliferator-Activated Receptors
PTSD Post-traumatic stress disorder
QUICKI Quantitative insulin check index
ROC Receiver operating characteristic
SGAs Second-generation antipsychotics
SMI Severe mental illness
SSRI Selective serotonin uptake inhibitor
TG Triglycerides
TPH2 Tryptophan hydroxylase 2
UA Uric acid
US United States
VPA Valproic acid
WC Waist circumference
WHO World Health Organization
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G. Ferns / Translational Metabolic Syndrome Research xxx (2018) 1e1623) Individuals being affected by SMI and MetS co-incidentally
because of shared common risk factors, that may include a ge-
netic predisposition,16 sleep disorders,17 or stress,18 that pre-
dispose to both psychiatric disease and metabolic
abnormalities.19
These putative mechanisms are not mutually exclusive; the re-
lationshipsmay be bidirectional and self-reinforcing (see Fig.1). For
example, whilst depression can predispose to CVD; CVD may also
lead to depression, and several socio-economic and behaviouralFig. 1. Interactions between factors related to severe mental illness (SMI) and ca
Please cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://docorrelates of both conditions may further inﬂuence this
relationship.20
In this review, these possible complex relationships are
explored further, together with the reported prevalence of MetS in
different SMIs (schizophrenia, schizoaffective disorder, bipolar
disorders, depression, stress related disorders and substance de-
pendency) and different global population samples. The interpre-
tation of prevalence estimates of MetS in populations with
psychiatric disease is complicated. This is particularly the case with
respect to historical and global data, because of the different criteriardiovascular disease (CVD) risk factors, including Metabolic Syndrome (MS).
idence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
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deﬁnitions over time, and the differences in these deﬁnitions be-
tween ethnic groups.24 Furthermore, the high frequency of unde-
tected co-morbidities, such as chronic liver disease, may confound
the interpretation of metabolic proﬁles in patients with psychiatric
disease.25 The potential impact of drug treatment for SMIs on the
risk of MetS is also explored, together with some of the potential
mechanisms that may account for this increased risk, using evi-
dence from different types of study. The review concludes with a
brief discussion of the possible approaches to the management of
CVD risk in patients with SMI, using drugs and lifestyle
interventions.
2. Prevalence of metabolic syndrome and its components in
mixed populations of psychiatric conditions [Table 1]
Some of the early papers on the relationship between psychi-
atric disease and MetS are reviewed below for completeness.
However, they often did not make a distinction between the cate-
gories of SMIs, and more recent studies have looked more carefully
at this, and do indeed report a signiﬁcant differential association.26
In a large, nationally representative group of 8028 Finns (>30
years old), the prevalence of MetS, using ATP III criteria, differed
between categories of SMI; prevalence estimates were 36.2%, 41.4%,
and 25.0% among subjects with schizophrenia, other non-affective
psychosis, and affective psychosis, respectively, and 30.1% for sub-
jects without psychotic disorders. The individuals with schizo-
phrenia had signiﬁcantly lower serum high-density lipoprotein
cholesterol (HDL-C) and higher triglyceride and glucose levels, and
larger waist circumference, than the other study groups. Among
subjects with other non-affective psychotic disorders, only the
difference in waist circumference was statistically signiﬁcant
(p < 0.05). The prevalence of MetS was signiﬁcantly higher among
users of high-potency antipsychotics (52.1%), but not for those on
low-potency (39.0%) and atypical (23.4%) antipsychotic medica-
tion.27 MetS was also reported to be more common amongst pa-
tients receiving poly-pharmacy with multiple antipsychotics andTable 1
Reported prevalence of metabolic syndrome in mixed groups of patients with serious m
Reference Suvisaari et al.27 Jin et al.32 Gossell-Williams et al.40 Ko e
Date 2007 2009 2012 2013
Country Finland USA Jamaica Sout
Setting Nationally
Representative
OP on
anti-psychotics
IP IP an
N 8028 203 38 1103
Age group >30 >40
Design CS CS CS CS
MS deﬁnition ATPIII AHA IDF/ AHA ATPI
iDF
%MS
Control 30.1
SMI 28.9 ATP
IDF 4
Schizophrenia 36.2 60
NA Psychosis 41.2
Aff Psychosis 25.0
Depression
BD
PTSD 72
Dementia 56
Anti-psych
High potency 52.1
Low Potency 39.0
Atypical 23.4
Aff ¼ Affective; AHA ¼ American Heart Association; ATPIII ¼ National Cholesterol Ed
Psych ¼ Antipsychotics; BD¼ Bipolar Disorder; CS¼ Cross-sectional; IDF¼ International
syndrome; NA ¼ non-affective; OP¼Out-patient; PTSD ¼ post-traumatic stress disorder
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syndrome, Translational Metabolic Syndrome Research (2018), https://domood stabilisers.8 In this same population, individuals with
schizophrenia also had a metabolically unfavourable body
composition, comprising abdominal obesity, high fat percentage
and low muscle mass.28
Data from a mixed population of in-patients with SMI from
Western Australia showed that the percentage of obese patients
(30.3%) was signiﬁcantly higher than for the general population
(21.4%), with women showing a greater propensity toward obesity
than men. In this sample, individuals with personality disorders
had a mean BMI in the obese range (30.07 kg/m2), and at a 9 month
follow-up, there were further increases in weight.29
Prior to the extensive use of antipsychotics, MetS was estimated
to be approximately two to three times more prevalent in SMIs
compared to the general population. However, the major psycho-
tropic drugs used to treat SMIs today may further exacerbate this
increased risk of MetS.30 In an Italian study, MetS was present in
35.2% in-patients with SMI, when deﬁned according to ATP III
modiﬁed criteria. The sample contained 29.6% of patients with
schizophrenia spectrum and other psychotic disorders, 37.6% of
those with bipolar and related disorders, 22.4% in depressive and
10.4% with personality disorders. Regression analysis, showed that
the use of atypical antipsychotic treatment was an important
determinant of MetS.31
There have been few studies that have compared prevalence
rates of metabolic abnormalities in patients with different psychi-
atric disorders being treated with antipsychotic drugs. In patients
(>40 years old) requiring antipsychotic treatment, the overall
prevalence rates of MetS were very high: 72% in patients with Post-
Traumatic Stress Disorder (PTSD), 60% in those with schizophrenia,
58% in those with mood disorder, and 56% in those with dementia.
The overall frequency of MetS and its components in patients with
PTSD taking antipsychotics was similar to that of patients with
schizophrenia.32 The 10-year risk of CHD, calculated using the
Framingham risk score, was also greatest in patients with schizo-
phrenia and PTSD in this population sample.33
A cross-sectional study investigated the prevalence of MetS
among psychiatric inpatients in Kashmir, Northern India. Theental illness.
t al.43 Solia et al.31 Hussain et al.35 Alosaimi et al.36 Saloojee et al.42
2015 2017 2017 2017
h Korea Italy India Saudi Arabia South Africa
d OP IP IP IP IP on anti-psychotics
125 213 992 232
CS CS
IIa ATPIIIa ATPIII JIS
43.9
0.1
35.2 34.7 41.2 F37.7
M10.3
31.0
43.3
37.9
63.6
ucation Programme, Adult Treatment Panel-III; ATPIIIa ¼ adapted ATP-III; Anti-
Diabetes Federation; IP¼ In patient; JIS ¼ Joint Interim Statement; MS ¼ Metabolic
; SMI ¼ severe mental illness.
idence: The relationship between psychiatric disease and metabolic
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with a psychiatric diagnosis based on the International Classiﬁca-
tion of Diseases, Tenth Revision (ICD 10) Classiﬁcation of Mental
and Behavioural Disorders criteria.34 The overall prevalence of
MetS was approximately 34.7%. It was higher in women (43.3%)
than men (28.5%) (p < 0.05) and increased with age. The highest
prevalence was among patients with unipolar depression (45.0%),
and was lower in patients with bipolar disorder (BD) (37.9%) and
psychotic disorders (31.0%). The prevalence of MetS was signiﬁ-
cantly higher (63.6%) among patients taking SGAs (p < 0.05).35
In a cross-sectional study conducted among adult patients with
psychiatric disorders at major hospitals in Saudi Arabia, the prev-
alence rate of MetS among the 992 study participants was 41.2%.
High fasted serum triglycerides were present in 32.8%, a high waist
circumference in 42.2%, high blood pressure in 42.5%, high fasting
blood glucose in 47.8%, and a low serum HDL cholesterol was found
in 52.5% of patients. Patients with MetS were more likely to be
older, illiterate, divorced or widowed, have a higher number of
children, older age of onset of psychiatric illness, longer duration of
psychiatric disease, no previous psychiatric hospitalization, and
have a history of diabetes and hypertension. After adjusting for
signiﬁcant demographic and clinical characteristics, none of the
psychiatric diagnoses and treatments was independently associ-
ated with MetS, except for the use of the anti-depressants, mirta-
zapine and venlafaxine.36
An Ethiopian cross-sectional study of 1924 adults, assessed
socio-demographic data, behavioural characteristics and major
depressive disorder (MDD) symptoms using the Patient Health
Questionnaire-9 (PHQ-9) depression scale.37 There were a total of
154 participants with MDD. Among women, MDD was associated
with more than 4-fold increased risk of diabetes mellitus
(OR ¼ 4.14; 95% CI: 1.0316.62). Among men the association was not
signiﬁcant (OR ¼ 1.12; 95% CI: 0.63e1.99); MDD was not associated
with MetS among women, or men in this population.38
A Swedish study of 731 patients with psychosis reported that
they had a signiﬁcantly higher waist circumference compared with
controls drawn from the same area, after controlling for fasting
insulin, differences in gender, blood pressure, fasting glucose,
family history of diabetes, age and tobacco use. An increased fasting
blood glucose was also more common in the psychotic patients
(OR ¼ 2.41; 95% CI 1.84e3.14) after controlling for confounding
factors.39 In a small sample (n ¼ 38) of Jamaican adult psychiatric
inpatients, the prevalence of MetS, using IDF criteria, was 28.9%.40
It has been reported previously that the prevalence of MetS is
higher among black women compared to black men living in South
Africa.41 This has been more recently investigated among black
South African participants with SMI (male 155 and female 77)
taking antipsychotic medication, and 232 matched controls
without SMI (male 156 and female 76). The Joint Interim Statement
(JIS) criteria were used to deﬁne MetS. The prevalence of MetS was
more than three times higher inwomenwith SMI compared tomen
with SMI (37.7% vs. 10.3%, p < 0.001). There was no signiﬁcant
difference in the prevalence of MetS in men or women between the
groups with and without SMI. In multivariate logistic regression
analysis, female gender (OR ¼ 7.66), advancing age (OR ¼ 1.08) and
longer duration of illness (OR ¼ 1.15) were signiﬁcant risk factors
for MetS in individuals with SMI. Hence, in black South Africans
with SMI on antipsychotic medication, there was a substantially
higher prevalence and risk for MetS in women compared to men.42
Data were collected from the medical records of 1103 inpatients
and outpatients treated for schizophrenia at Seoul National Hos-
pital in Seoul, Korea. MetS prevalence data were compared by
gender, age, MetS components, treatment for these components,
and types of antipsychotics and individual drugs used. The preva-
lence of MetS in all subjects was 43.9% and 40.1% according toPlease cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://doadapted ATP-III (ATPIIIa) and IDF criteria, respectively. No signiﬁ-
cant differences were found in prevalence according to ATP-IIIa
criteria between men (42.6%) and woman (45.9%). A trend toward
a higher prevalence with age was observed for both sexes up to 50
years, followed by a continued increase for women but a decrease
for men. Use of a combination of atypical antipsychotics was
associated with the highest MetS prevalence and use of aripipra-
zole with the lowest.43
In these studies of populations with mixed SMI, a higher prev-
alence of MetS above the background has been reported in popu-
lation samples from Europe, Asia and Africa. This appears to be
affected by gender, ethnicity and category of SMI, together with the
drug therapy used (SGAs, atypical antipsychotics and poly-
pharmacy).3. Prevalence of metabolic syndrome and associated features
in patients with schizophrenia [Table 2]
Schizophrenia is a severemental disorder that affects more than
20million individuals globally.44 It is associatedwith “distortions in
thinking, perception, emotions, language, sense of self and behav-
iour.” People with schizophrenia can experience both hyper- and
hypo-function of the HPA axis. It is likely that this contributes to the
pattern of poor physical health and premature mortality that they
suffer, in particular the high rates of cardiovascular and metabolic
disturbance.45 It has been estimated that schizophrenia is associ-
ated with a 20 year reduction in lifespan, with an increased prev-
alence of type 2 diabetes mellitus and CVD contributing themost to
the increased mortality.46 Unrecognised, or silent myocardial
infarction (MI) appears to occur frequently among patients with
schizophrenia and this may also contribute to the increased mor-
tality in this patient group.47
Baseline data from the Oslo TOP Study (including individuals
with BD [N ¼ 110] and schizophrenia [N ¼ 163]) were compared to
reference data, obtained from the Oslo Health Study in 2001
(comprising 18,770 individuals who were drawn from the same
locality). There was no signiﬁcant difference between the two
diagnostic groups, with respect to the prevalence of smoking,
obesity, MetS, or diabetes. However both diagnostic groups had a
prevalence of cardiovascular risk factors about twice that of the
general population.48
The prevalence of the MetS among 136 adults with schizo-
phrenia and schizoaffective disorder who were admitted to an
acute psychiatric ward in 2004 was assessed together with the
socio-demographic and psycho-pharmaceutical variables in a
University Hospital in Gran Canaria, Spain. The prevalence of MetS,
deﬁned according to NCEP-ATP III criteria was 36% and increased
with age (p < 0.05). Ten year coronary risk was moderate or high in
a large percentage of patients, and was associated with the use of
antipsychotics.49
Baseline data from the Clinical Antipsychotic Trials of Inter-
vention Effectiveness (CATIE) Schizophrenia Trial was used to
assess the prevalence of MetS by the ATPIII and AHA criteria in
patients with SMI. This was reported to be 40.9% and 42.7%,
respectively. The prevalence was 51.6% and 54.2%, among women,
signiﬁcantly higher than for men, who had prevalence values of
36.0% (p ¼ 0.0002) and 36.6% (p ¼ 0.0003), respectively. Logistic
regression analysis, with age, race and ethnicity as covariates,
showed that men and women were 138% and 251% more likely to
have MetS than matched controls from the NHANES cohort.50
In a Belgian study of 430 patients with schizophrenia admitted
to a university psychiatric hospital, the prevalence of the MetS as
28.4% (ATP-III), 32.3% (ATP-III a) and 36% (IDF), respectively, at least
two-fold higher than for an age-adjusted community sample.51idence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
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syndrome, Translational Metabolic Syndrome Research (2018), https://doOf 143 patients (older than 20 years) with schizophrenia
admitted to an inpatient unit, ﬁfty-two (36.4%) patients fulﬁlled the
criteria for MetS. These patients also had a high prevalence of
cardiovascular risk factors.52
Because of the potential for anti-psychotic drugs to alter the
component features of MetS, prevalence studies have been un-
dertaken in patients with a ﬁrst episode of schizophrenia (FES).
These patients were found to have a wide range of metabolic ab-
normalities. Although patients with FES (n ¼ 84) showed a similar
prevalence of MetS as a matched control sample (n ¼ 98) (6% vs.
4%), measures of glucose homeostasis differed signiﬁcantly (14% vs.
5%, P ¼ 0.034). This suggests that abnormal glucose homeostasis
may be an early marker for the onset of MetS in this group; MetS
may not develop until the initiation of pharmacological treatment
with antipsychotics, or with advancing age.53 These data are
consistent with another study on patients with FES in which the
changes and predictors of MetS were monitored during the year
following the initiation of treatment. MetS was deﬁned according
to IDF criteria. Baseline prevalence of MetS in the FES patients was
higher than in controls but did not attain signiﬁcance (p ¼ 0.07);
however, metabolic and anthropometric parameters were signiﬁ-
cantly higher: WC (p < 0.01), TG (p < 0.01), HDL (p ¼ 0.017), and
fasting glucose (p ¼ 0.04). The increased prevalence of MetS at
follow-upwas signiﬁcant (p¼ 0.03). Treatment with antipsychotics
and low physical activity were signiﬁcantly related with these
changes in metabolic abnormalities.54
A comparison has been made of the prevalence of diabetes
mellitus (DM) in patients with schizophrenia attending a commu-
nity mental health centre, with controls drawn from the same
metropolitan area. The effects of antipsychotic exposure on the
prevalence of diabetes mellitus were also investigated. These pa-
tients were found to have a higher average BMI than the controls
(32.11vs 27.62 kg/m2), a signiﬁcantly higher percentage of obesity
(58.5% vs. 27%, P < 0.001) and a signiﬁcantly higher prevalence of
DM (23.9% vs. 12.2%). This remained signiﬁcant even after con-
trolling for age sex, race, and for obesity (OR ¼ 1.82, P ¼ 0.001). The
distribution of antipsychotic dosage, second generation antipsy-
chotic (SGA) use or multiple antipsychotic use within different BMI
categories or with diabetes status did not have a signiﬁcant impact
in the schizophrenia group, and the authors therefore suggest that
antipsychotics may not be the only contributor to this risk of DM.55
A cross-sectional study, of 319 Turkish patients (aged 18e75
years), with a diagnosis of schizophrenia, reported that 34.2% pa-
tients met the ATP-III criteria, 37% the ATP-IIIa and 41.7% the IDF
criteria for MetS. Patients with MetS had a later onset of illness and
were older at the time of ﬁrst hospitalization. The prevalence of
MetS in the schizophrenia patients was higher than for the general
population, but only signiﬁcantly so within the 20e29 age group.56
Among 650 patients with schizophrenia or schizoaffective dis-
order recruited from 36 psychiatric institutions in Taiwan, the
prevalence of MetS was 34.9% (38.9% in women and 31.5% in men
respectively), based on the modiﬁed ATPIII criteria for Asians. The
difference in MetS prevalence between the patient sample and the
general population was marked in male patients under 40 years of
age and in female patients under 50 years old. A BMI 24 and age
40 years old were important risk factors for MetS. Female gender
and poly-pharmacy were marginally signiﬁcant factors in this
population sample.57
MetS prevalence was assessed among 1186 Japanese patients
with schizophrenia or schizoaffective disorder and 886 controls.
The patients were recruited from seven psychiatric hospitals, and
MetS, was deﬁned using three different deﬁnitions, including the
ATP IIIa deﬁnition. The total prevalence of MetS, based on the ATP
IIIa deﬁnition was 27.5% (29.8% in male and 25.3% in female pa-
tients). Logistic regression analysis showed that the presence ofidence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
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ratio ¼ 2.00 for males, 2.13 for females) for the development of
MetS.58
In a sample of 100 patients with schizophrenia and 300 com-
munity controls from Singapore, the prevalence of MetS in patients
with schizophrenia was reported to be 46.0%. The adjusted odds
ratio for MetS among patients was 2.79 (CI, 1.50e5.20, P ¼ 0.001)
when compared with controls.59 A further study from Singapore
determined the cardio-metabolic risk proﬁle and the associated
risk factors for a group of institutionalized patients with schizo-
phrenia or schizoaffective disorder receiving prolonged hospital
care. The prevalence of MetS in this group was 51.9% and 26.9%
based on the AHA/NHLBI and modiﬁed NCEP ATP III criteria
respectively. 10-year cardiovascular risk was estimated at 12.8%,
indicating an intermediate risk based on the Framingham risk al-
gorithm. There was no signiﬁcant association with the use of
atypical antipsychotic drug therapy and the duration of hospitali-
zation did not affect the rate of MetS in this sample.60
The prevalence of MetS was investigated among patients with
schizophrenia in Palestine. Two hundred and ﬁfty patients with
schizophrenia were recruited from 4 psychiatric primary health-
care centres in Northern Palestine. The presence of MetS was
assessed based on ATPIIIa criteria. The overall prevalence of MetS
was 43.6%, (39% of men and 55.9% of women). Univariate analysis
showed that MetS increased signiﬁcantly with age, female gender,
longer duration of the illness, a positive smoking habit, abdominal
obesity, high systolic and diastolic blood pressure, high tri-
glycerides, low HDL-C, and high fasting plasma glucose.61
A large Japanese study involved the recruitment of 7655 out-
patients and 15,461 in-patients with schizophrenia, who were
recruited from 520 outpatient facilities and 247 inpatient facilities
of the Japan Psychiatric Hospitals Association between 2012 and
2013. The outpatients had signiﬁcantly higher prevalence of
obesity, hypertension, hypertriglyceridemia, high-LDL-C, and DM
than the inpatients. The prevalence of low-HDL-C was higher in
inpatients than outpatients. Age-speciﬁc analysis showed the
prevalence of obesity, hypertension, hypertriglyceridemia, high-
LDL-C, and DM among outpatients to be 2-3-fold-higher than
among inpatients. In individuals aged 60 years, the prevalence of
obesity and DM among outpatients was about 3-fold higher than
among inpatients.62
Serum uric acid (UA) is derived from purine metabolism, and
hyperuricaemia may be associated with gout. Gout itself is associ-
ated with an increased risk of CVD,63 but hyperuricaemia has also
been frequently reported to be associated with MetS in population
studies.64 However, there appear to be differences in this associa-
tion between genders and ethnicities.65 Serum UA has been found
to be reduced in patients with schizophrenia,66 and this has been
attributed to altered purine catabolism and treatment with anti-
psychotics67; but serum UA has been reported to be raised in pa-
tients with bipolar disease.68 In an Asian study, 637 patients (342
male) were recruited from 36 psychiatric rehabilitation in-
stitutions. Serum UA concentrations were positively associated
with hypertriglyceridemia, low high-density lipoprotein choles-
terol level, and high blood pressure in men and with hyper-
triglyceridemia in women. In men with schizophrenia or
schizoaffective disorder lower concentrations of serum uric acid
were associated with lower risk of MetS.69
The assessment of central adiposity is an important feature for
deﬁning MetS. A cross-sectional study of 382 inpatients with
schizophrenia-related disorders assessed the prevalence of each
component of MetS. In this analysis, WC was measured at several
sites. Logistic regression analysis was used to assess the ability of
WC at each site to predict the presence of metabolic risk clustering.
The site of measurement of WC inﬂuenced the estimatedPlease cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://doprevalence of abdominal obesity (30e38.2% inmen and 53.9e86.3%
in women) and of MetS. The areas under the ROC curve for meta-
bolic risk clustering were highest for the measurement ofWC at the
umbilicus and midpoint.70
High sensitivity C-reactive protein (hs-CRP) is a serum inﬂam-
matory marker synthesised in the liver and positively associated
with CVD and mortality.71 Serum hs-CRP levels were reported to be
signiﬁcantly higher in individuals with schizophrenia than in
healthy control subjects, and its levels were associated with more
severe symptoms, greater medical co-morbidity, andmetabolic risk
factors, including BMI, and fasting glucose, that were also more
severely disturbed.72
Hence schizophrenia is associated with an increased risk of CVD
and/orMetS in European and Asian populations. It is also associated
with other features of MetS, including hyperuricaemia and raised
serum hs-CRP, both of which are also risk factors for CVD. Abnor-
malities in glucose homeostasis are evident in FES, before treat-
ment with antipsychotics has started, and therefore there are likely
to be other contributors to the risk of DM and MetS apart from the
use of anti-psychotic drugs in these patients.4. Prevalence of metabolic syndrome and associated features
in patients with bipolar disorders [Table 3]
BD is an episodic mood disturbance with a chronic course and
multisystem involvement. Disturbances of circadian rhythms,
mood instability, cognitive impairment, and a high rate of medical
co-morbidity are often observed. BD is also associated with a high
prevalence of psychiatric comorbidity and an increased mortality
from physical disease,73 particularly in older patients.74 Whilst
there is a high prevalence of comorbid physical and psychiatric
disorders in patients with BD; these do not appear to affect the
relapse risk in patients with BD, theymay however further enhance
the risk of MetS.75
In an early report, the point prevalence of MetS, deﬁned using
WHO criteria was determined in 33 patients with schizoaffective
disorder-bipolar type, who were recruited into a clinical drug trial,
was reported to be higher than for the general population of the
USA.76
In studies of cardiovascular and all-cause mortality, BD has been
associated with an approximate doubling of risk in both men and
women compared to general population estimates, and an 8e9
year reduction in lifespan.2 This may be partly explained by the
elevated burden of CVR factors found in this population, and these
early ﬁndings predate modern treatments for BD, which may
further exacerbate CVR.77 Suicide risk has been reported to be 10-
fold among women and 8-fold among men with BD, compared
with the rest of the population.2
The cardiovascular mortality among people with BD compared
to the general population in Sweden was investigated using a
population register-based cohort study with a 20-year follow-up.
The entire population of Sweden (n ¼ 10.6 million) was included,
of whom 17,101 individuals were diagnosed with BD between 1987
and 2006. Individuals with BD died of CVD approximately 10 years
earlier than the general population. Despite the increasedmortality
from CVD, hospital admissions for CVD treatment were only
slightly increased in people with BD when compared to the general
population.78
In a European cross sectional study, the prevalence of MetS
among patients with BD was assessed using ATP-III, the ATP-IIIa
criteria using a fasting glucose threshold of 100 mg/dL, and the
most recently proposed criteria from the International Diabetes
Federation (IDF). The prevalence of MetS was of 16.7% (ATP-III),
18.3% (adapted ATP-III) and 30.0% (IDF), respectively.79idence: The relationship between psychiatric disease and metabolic
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Table 3
Reported prevalence of metabolic syndrome in patients with bipolar disease and depression.
Reference Basu et al.76 Bermudes et al.98 Van Winkel et al.79 Chang et al.81 Guan et al.83 Lee et al.84 Ezzaher et al.82 Kim et al.100 Lasserre et al.97
Date 2004 2006 2008 2009 2010 2010 2011 2015 2017
Country USA USA Belgium Taiwan China Korea Tunisia Korea Switzerland
Setting Drug trial IP OP and IP OP OP and IP OP OP and IP OP OP
N 33 122 60 majority on
Anti-psychotics
117 treated with
valproate, lithium
or both
148 BP
65 C
152 BP 130, >70% treated
with mood stabilizers
13,745 2813
Age group >21 >18 >21 >21 >21 >21 >18 40e59 35e66
Design CS CS CS CS CS CS CS Cohort Study Cohort Study
MS deﬁnition WHO ATPIII ATPIII
ATPIIIa
IDF
IDF Chinese
Med Assoc
ATPIII
AHA
IDF
ATPIIIa
%MS
Control ~10.0
Depression 38.6
BD 42.5 16.7
18.3
30.0
33.9 11.5 25.0
27.0
25.7
26.1
AHA ¼ American Heart Association; ATPIII ¼ National Cholesterol Education Programme, Adult Treatment Panel-III; ATPIIIa ¼ adapted ATP-III; BD¼ Bipolar Disorder;
CS¼ Cross-sectional; IDF¼ International Diabetes Federation; IP¼ In patient; MS ¼ Metabolic syndrome; OP¼Out-patient; PTSD ¼ post-traumatic stress disorder;
SMI ¼ severe mental illness.
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BD was signiﬁcantly higher than in the general population (be-
tween 36 and 49% in the USA), and could be explained by several
determinants, including reduced physical activity and poor diet,
genetic susceptibility, psychiatric comorbidity and anti-
psychotropic treatment. Patients with BD have disturbances of
the circadian cycle and sleep. These latter disturbances are known
to persist even during periods of mood stabilization and are found
in the relatives of these patients, suggesting a genetic contribution
to sleep disturbance. The circadian and sleeping disorders may
affect the prevalence of MetS in BD, possibly due to a linkage to
leptin and ghrelin dysregulation. Prevention and treatment of
circadian disorder in BD may reduce the occurrence of MetS in
these patients.80
A high prevalence of obesity and metabolic disturbances have
been reported in patients with BD in Western countries, although
there have been few studies in Asian countries. A cross-sectional
study of 117 patients diagnosed with BD and treated with
lithium, valproate, or both was undertaken at a University psychi-
atric outpatient clinic in Taiwan. It was found that 33.9% of the
patients met the IDF 2005 criteria for MetS. The prevalence of
metabolic abnormalities was signiﬁcantly higher in patients who
were co-treated with second-generation antipsychotics (SGAs).81
The prevalence of MetS in Tunisian patients with BD (n ¼ 130)
was assessed for MetS according to ATPIII modiﬁed criteria, and
was found to be 26.1%. The highest prevalence of MetS was asso-
ciated with obesity, low HDL-C and hypertriglyceridemia (44.1%).
Patients treated with lithium had a higher prevalence of MetS than
those treated with valproic acid (VPA), carbamazepine or
antipsychotics.82
The prevalence of MetS and its correlates was also investigated
in patients with BD from southern China, during their acute-phase
of treatment. The study included 148 patients with BD presenting
with acute mood symptoms and 65 healthy controls. Chinese
Medical Association Diabetes Branch criteria were used to deﬁne
MetS. MetS prevalence rates were calculated at entry and recalcu-
lated for patients after months 1, 3, and 6. At baseline, MetS was
found in 11.5% of the patients; overweight in 34.5%; low high-
density lipoprotein cholesterol in, 15.5%; hypertriglyceridemia in
29.1%; hypertension in 14.9%; and hyperglycemia in 5.4%.
Compared with controls, the patients had a signiﬁcantly higher
prevalence of MetS and all its components apart fromPlease cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://dohyperglycemia (P < 0.05). In the regression analysis, a history of
hypertension, presence of diabetes, and alcohol consumption were
associated with the presence of MS.83
Korean patients with BD were investigated to assess the co-
morbidity of BD with MetS, and to compare the prevalence of
MetS in patients on medication for BD with that of healthy patients
in Seoul National University Hospital between 2007 and 2008. The
control group, matched for age and gender, was randomly drawn
from visitors to the Health Promotion Centre at the same hospital
during the same period. The prevalence of MetS in patients who
took medication for BD was 27.0%. 25.0% and 25.7%, based on the
deﬁnitions of the American Heart Association and the National
Heart, Lung and Blood Institute's adaptation of the ATP IIIa, the
ATPIII and the IDF, respectively. The prevalence of MetS was
signiﬁcantly higher in patients with BD than in the control group.
Patients on medications for BD showed a signiﬁcantly higher
prevalence of increased waist circumference, elevated triglyceride,
and lower HDL-cholesterol than the controls. Obesity and dyslipi-
daemia were particularly prevalent in patients with BD.84
It is therefore apparent that MetS and BD share common risk
factors, including endocrine disturbances, dysregulation of the
sympathetic nervous system, and altered behaviour patterns, such
as sedentariness and overeating. This may partially account for the
increased risk of hypertension in BD, reported by Ayerbe et al. in
their meta-analysis.85 Many of the commonly used drug treatments
for BD may further exacerbate weight gain and metabolic distur-
bances in bipolar patients by causing alterations in lipid and
glucose metabolism, which can result in an increased risk for DM,
hypertension, dyslipidaemia, CVD and MetS. A recent meta-
analysis also suggests that antidepressant use is associated with
new onset DM.86 These co-morbidities may be associated with the
premature mortality observed in bipolar patients. Furthermore,
weight gain is also a major cause of treatment non-compliance, and
an increased use of clinical services.87
There appear to be gender effects that determine the risk of
dyslipidaemia and IR in patients with BD. In a study of 491 out-
patients (ages 18e88) attending the Stanford Bipolar Disorders
clinic between 2000 and 2007, women had a signiﬁcantly lower
prevalence of dyslipidaemia than men.88
Serum C-Reactive Protein (CRP) and homocysteine are both in-
dependent risk factors for CVD. A meta-analysis comprising 11
studies and 1618 individuals showed that serum CRPidence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
Table 4
Reported prevalence of metabolic syndrome in patients with other serious mental illness and on treatment with antipsychotics.
Reference Linnville
et al.109
Heppner
et al.108
Elmslie
et al.125
Margari
et al.122
Ojala et al.
116
Taylor
et al.129
Brunero
et al.119
Correll
et al.117
Krane-
Gartiser
et al.118
Correll
et al.127
Saddichha
et al.131
Vandenberghe
et al.142
Popovic
et al.143
Munshi
et al.114
Lin
et al.115
Eskelinen
et al.144
Date 2011 2009 2009 2013 2008 2010 2009 2006 2011 2008 2008 2015 2015 2015 2015 2015
Country USA USA New
Zealand
Italy Finland Canada Australia USA Denmark USA India Serbia Canada Taiwan Finland
Setting OP OP OP Forensic
Psychiatry
IP
IP OP IP OP IP IP IP OP
N 351 veterans
with no other
Psychiatric
Co-morbidity
233 veterans
Mostly male
and white
60 BD on
val-proate
60 non-
psychia-tric
controls
83
Schizophrenia
24
BD 27
MDD 14
Other 18
77 C internal
med
221 54
Mania or
Depression
104
NHANESIII
control data
73 patients
on clozapine
367 170
Patients on
anti-
psychotics
3303
controls
111
Schizo
phrenia
74 BD
On anti-
psychotics
99 351 93 patients
with
schizophrenia
on treatment
with
olanzapine
50
patients
80% on
SGA
329
patients
with
schizo-
phrenia
on SGA
276 patients
with
schizophrenia
High % on
clozapine
Age group >~50 >21 16e40 >21
Design CS but 25
years after
initial
recruitment
CS Matched
Control
CS
Matched
control
Cohort
Matched
control
CS
DB
Controlled
trial
CS casee
control
CS CS CS
MS deﬁnition ATPIIIa ATPIII ATPIII IDF IDF ATPIII
ATPa
ATPIIIa
IDF
IDF IDF IDF IDF
%MS 48
Control 25 32 Baseline 19
Follow-up 14
29.6
SMI 62 22 at
baseline
Schizo-
phrenia
45.9
54
10
18
23.7 58.7
NA
Psychosis
Aff
Psychosis
Depression 29 Baseline 15
follow-up 17
BD 50 Baseline 5
follow-up 15
43.2
54
PTSD 25 34
(46 if
plus MDD)
Anti-Psych 37 48 32 after
1 year on
treatment
34.4
AHA ¼ American Heart Association; ATPIII ¼ National Cholesterol Education Programme, Adult Treatment Panel-III; ATPIIIa ¼ adapted ATP-III; BD¼ Bipolar Disorder; CS¼ Cross-sectional; FES¼ First episode schizophrenia;
IDF¼ International Diabetes Federation; IP¼ In patient; MS ¼ Metabolic syndrome; OP¼Out-patient; PTSD ¼ post-traumatic stress disorder; SMI ¼ severe mental illness.
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G. Ferns / Translational Metabolic Syndrome Research xxx (2018) 1e16 9concentrations are signiﬁcantly raised in patients with BD and
unrelated to drug treatment.89 In 122 patients with bipolar (n¼ 60)
and schizophrenia (n ¼ 62) treated with second-generation anti-
psychotics (SGA) and healthy controls (n ¼ 59), the prevalence of
MetS (using ATP-III criteria) was associated with hyper-
homocysteinaemia, which conferred a >8 fold risk of MetS.90
5. Prevalence of metabolic syndrome and associated features
in patients with depression [Table 4]
Depression is associated with an increased risk of premature
death, death from unnatural causes91 and CVD.92 In a review
reporting on the MetS prevalence in major depressive disorders
(MDD), MetS was found in approximately 30.5% of patients using
any of the standardized MetS criteria. This was approximately 1.5
fold that for age-and gender-matched controls Antipsychotic use
was a signiﬁcant determinant of the increased prevalence of MetS
(p < 0.05), whereas age, gender, geographical area, smoking habit,
antidepressant use, and presence of psychiatric co-morbidity, were
not.93 Patients with a long history of depressive symptoms have a
lower serum HDL-C and higher atherogenic lipid indices compared
with healthy controls.94 In a cross-sectional study of 133 older
people, Viscogliosi et al. found that the presence of MetS and serum
hs-CRP were independently associated with depressive
symptoms.95
The CoLaus/PsyCoLaus prospective cohort study showed that an
atypical form of MDD96 was prospectively associated with a higher
incidence of the MetS and a steeper rise of fasting glucose during
follow-up. Perhaps surprisingly these associations were found not
to be due to eating behaviours, comorbid psychiatric disorders or
lifestyle factors.97
The prevalence of the MetS in a recent survey of psychiatric in-
patients with severe mood and psychotic disorders, showed that
among 102 consecutively adult patients admitted with a primary
diagnosis of a mood or psychotic disorder, the prevalence of MetS
was 38.6%, and was associated with increasing age, body mass in-
dex, and Caucasian ethnicity.98
A cross-sectional study of adult patients with depression found
that the prevalence of overweight and obesity was 72% in patients
with longer duration of disease, also being associated with a higher
BMI and percentage fat mass. Weight gain during the illness was
found in 87% of patients; and was at least partially attributable to: a
poor diet, with a regular consumption of high calorie foods; the use
of anti-in these patients depressants and benzodiazepines, and
insufﬁcient physical activity.99
In a retrospective cohort study included 13,745 subjects (8113
men and 5632 women) 40e59 years of age who were investigated
at the Seoul National University Hospital Healthcare System, in
Korea. The median follow-up duration was 4.0 years. Four distinc-
tive trajectories of depressive symptoms were identiﬁed, that were
present in both genders. There was a signiﬁcant increasing trend in
the prevalence of metabolic abnormalities in those patients with a
more severe trajectory of depressive disease, and this was also
associated with MetS.100
Both MDD and the MetS are associated with a genetic sus-
ceptibility and impaired serotonergic neurotransmission in spe-
ciﬁc areas of the brain. The variants in the genes encoding
tryptophan hydroxylase 2 (TPH2) (the brain-speciﬁc and rate-
limiting enzyme for serotonin biosynthesis), was investigated in
988 patients with recurrent unipolar depression and 1023 psy-
chiatric healthy controls. TPH2 polymorphisms were found to
deﬁne a sub-group of depressed patients who may be susceptible
to developing metabolic disorders. The authors propose that this
may be induced by a genotype-dependent impairment of sero-
tonergic neurotransmission.101Please cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://doA small cross-sectional study of patients with chronic MDD,
acute MDD and controls, reported that the patients with chronic
MDD had highest volumes of pericardial adipose tissue (PAT).102
PAT volume has been implicated in the development of coronary
artery disease, and was found to be positively associated with ad-
renal gland volume. Patients with chronic MDD also had the higher
prevalence of MetS and levels of serum cortisol and pro-
inﬂammatory cytokine concentrations. Hence, the hypothal-
amusepituitaryeadrenal axis may have a central role in the rela-
tionship between chronic MDD and coronary artery disease.
The numbers of studies on the effects of antidepressants on the
features and prevalence of MetS are limited. Using data from the
Hordaland study, Raeder et al. found that some selective serotonin
re-uptake inhibitors (SSRIs), for example paroxetine, were associ-
ated with abdominal obesity.103 Dortland and colleagues have re-
ported that the use of tricyclic antidepressants are also associated
with the risk of MetS independently of the severity of depres-
sion.104 A large French cohort study reported the risk of MetS in
men and women treated with antidepressants over 9 years.105
There was a signiﬁcantly higher risk of MetS in men but not
women, and for those taking SSRIs.
6. Metabolic syndrome in patients with post-traumatic stress
[Table 4]
Post-traumatic stress disorder (PTSD) is a mental disorder that
may arise following exposure to a traumatic event, that may be
physical (e.g. war injury), or psychological (sexual abuse), and leads
to disturbed thoughts and dreams, and physical andmental distress
in response to particular cues.106 PTSD is associated with somatic
disease and a shortened lifespan, and obesity, dyslipidaemia, hy-
pertension, DM, and CVD are prevalent among patients with
PTSD.107 In patients with combat-related PTSD, who developed
MetS, there were higher rates of anxiety, depression and recent life
changes scores compared to those without.18 Among 253 veterans
from the USA, a high prevalence of MetS was found in those with
PTSD alone (34%), MDD alone (29%), and particularly those with
PTSD andMDD combined (46%).108 The rates of MetS were reported
to be particular high in those with more severe PTSD.
In contrast, a retrospective analysis of metabolic data for
Vietnam-era repatriated prisoners of war (RPWs) found that the
prevalence of MetS was the same in RPWs with and without PTSD
and a comparator group. Moreover, PTSD symptom severity did not
increase the likelihood of MetS in this study.109 However this latter
study excluded individuals with other psychiatric co-morbidities.
The potential effects of antipsychotic drug usage, particularly
SGAs on the risk ofMetS and obesity, may account for some if not all
of the observed metabolic problems in PTSD. A cross-sectional
study investigated this in veterans enrolling in mental health ser-
vices. Antipsychotic medication usage was not associated with
elevated risk of MetS when PTSD severity and other socio-
demographic, psychiatric, and behavioural variables were accoun-
ted for. PTSD severity continued to be a signiﬁcant and unique
predictor of risk for MetS (p < 0.05).110
7. Prevalence of metabolic syndrome in patients with
substance dependency
Individuals with alcohol use disorders (AUDs) have an increased
risk for CVD and associated premature mortality. MetS and its
components were investigated in a meta-analysis of people with
AUDs taking into account variations in demographic and clinical
variables. The pooled MetS prevalence after adjusting for publica-
tion bias was 21.8%; abdominal obesity was observed in 38.3%,
hypertriglyceridemia in 43.9%, low high-density lipoproteinidence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
G. Ferns / Translational Metabolic Syndrome Research xxx (2018) 1e1610cholesterol in 7.6% and hypertension in 46.5%. A meta-regression
analysis showed that a higher MetS frequency was associated
with a higher frequency of psychiatric co-morbidities.111
8. Stress and metabolic syndrome and its components
Stress may cause some people to eat less and lose weight and
others to eat more. Using longitudinal data, the effects of work-
related stress was assessed in the Whitehall II study cohort,
comprising 5547men and 2418 women, aged 35e55 at entry. Work
stress, assessed using a job strain model, and measured as job
control, job demands and job strain, was assessed at baseline and
BMI at baseline and at 5-year follow-up. In men, the effect of job
strain on weight gain and weight loss was dependent on baseline
BMI (P < 0.03). In the leanest quintile (BMI 22 kg/m2) at baseline,
high job strain and low job control were associated with weight
loss, whereas among those in the highest BMI quintile (BMI
>42.7 kg/m2), these stress indicators were associated with weight
gain. The interaction was not seen among women.112
In a cross-sectional study of 1822 obese outpatients seeking
treatment in medical centres, health related quality of life (HRQL)
was measured by summary scores for physical (PCS) and mental
(MCS) components of the Short Form 36 Health Survey (SF-36).
Patients were grouped according to tertiles of PCS and MCS.
Metabolic and psychological proﬁles of tertiles for PCS and MCS
were compared by discriminant analysis. The main correlates of
PCS were obesity-speciﬁc and general psychological well-being,
BMI, binge eating, gender and psychiatric distress. Hypertension
and hyperglycemia were signiﬁcant correlates among the compo-
nents of MetS. Features of MetS correlate with the physical domain
of HRQL to some degree.113
9. Effects of antipsychotic drug treatment on the risk of
metabolic syndrome
The use of atypical antipsychotic drugs in patients with psy-
chiatric illness may result in dyslipidaemia, hypertension, glucose
intolerance, and abdominal obesity. This has been investigated
using cross-sectional, caseecontrol and cohort studies.
9.1. Cross-sectional studies
In an acute care psychiatry inpatient unit at Kingston General
Hospital, Ontario, Canada, and comprised adult patients of both
genders diagnosed using the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition. MetS was deﬁned using the IDF
criteria. Of the 50 patients in the study, 24 (48%) were found to have
MetS, of whom 83% were taking atypical antipsychotics and 20
(77%) among those were not on these drugs.114
Three hundred and twenty nine Han Chinese patients were
recruited from a psychiatric hospital in central Taiwan. Using the
deﬁnitions of the IDF for Chinese, the prevalence of MetS was 23.7%
(men: 25.7%; women: 21.2%). An abnormal non-HDL-C was a sig-
niﬁcant risk factor for menwithMetS (OR: 4.127, p < 0.001), but not
for women. There was a greater prevalence of MetS in patients with
schizophrenia taking SGAs than in the general population.115
The prevalence of MetS and its risk determinants was investi-
gated among 221 Finnish psychotic forensic psychiatric inpatients
with comorbidities of antisocial personality or alcohol dependence.
Schizophrenia, or a related psychosis was the predominant diag-
nosis (92%), and these patients had been on constant SGA medi-
cation for the previous over six months. The use of clozapine (OR
8.1), quetiapine (OR 7.7), and olanzapine (OR 3.6) was associated
with an increased occurrence of MetS. A beneﬁcial high-density
lipoprotein cholesterol proﬁle was found with the use of selectivePlease cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://doserotonin uptake inhibitor (SSRI), and with a diagnosis of alcohol
dependence, even after alcohol abstinence. MetS was associated
with the use of clozapine and quetiapine.116
Three hundred and sixty seven adults treated with second-
generation antipsychotics randomly selected from consecutive
psychiatric admissions to a single hospital, underwent assessments
evaluating the presence of MetS. MetS, was found in 137 patients
(37.3%), and was associated with a signiﬁcantly greater age- and
race-adjusted 10-year risk of CHD events, i.e., 11.5% vs. 5.3% for men
and 4.5% vs. 2.3% for women.117
The prevalence of the MetS in an Outpatients psychiatric clinic
in Denmark, was compared to the general population in
2007e2008, 170 Danish outpatients on antipsychotic drug treat-
ment were assessed for the prevalence of theMetS based on the IDF
deﬁnition and compared with a general population of 3303
randomly selected Danes. Of the antipsychotic-treated patients,
48.2% fulﬁlled the IDF criteria for the MetS, compared with 29.6% of
the general population. The antipsychotic-treated patients had
higher rates of increased waist circumference, triglyceride and
glucose levels, and lower high-density lipoprotein cholesterol. The
odds ratio (OR) of the MetS among patients treated with antipsy-
chotics was 2.2. After adjustment for age and sex, the OR increased
to 2.7. There were statistically different rates of the MetS for pa-
tients on mono-pharmacy vs. poly-pharmacy, and for patients on
mono-therapy with ﬁrst-generation vs. second-generation
antipsychotics.118
The prevalence and predictors of MetS were studied in patients
attending an outpatient clozapine clinic in Australia: Seventy-three
patients were screened for MetS using the IDF (2007) deﬁnition,
61.6% patients met the criteria for the syndrome.119
A recent study has reported that serum CRP levels are higher in
patients treatedwith some atypical antipsychotic medications such
as olanzapine; however, it was unclear whether this was directly
associatedwith drug intake, or indirectly related to drug-associated
weight gain and insulin resistance. Sixty-four outpatients without
diabetes being treated with a single second generation antipsy-
chotic medication was investigated. IR was the strongest predictor
of serum CRP (r ¼ 0.52, P < 0.001), and after adjustment for this
there was no signiﬁcant relationship between CRP and any of the
components of the MetS.120
9.2. Case-control studies
The metabolic proﬁles of patients with schizophrenia taking
atypical antipsychotics were compared to their siblings, and con-
trols (N ¼ 50 in each group). Patients with schizophrenia had a
signiﬁcantly higher body mass index, waist circumference, and
insulin resistance, and showed a trend toward a difference in
glucose levels.121
Eighty-three psychiatric in-patients under pharmacological
treatment (schizophrenia, n ¼ 24, BD, n ¼ 27, MDD, n ¼ 14, and
other, n ¼ 18) were compared with 77 internal medicine patients.
Triglycerides and triglycerides/HDL ratio were higher in the pa-
tients with MDD. A positive association was found between anti-
depressant drug treatment and triglycerides and triglycerides/HDL
ratios, neuroleptic treatment with the Homeostatic model assess-
ment (HOMA) index, and antipsychotics drugs with the overall
Framingham risk score.122
In a caseecontrol study of 90 people treated with antipsychotics
in the community and 92 age- and gender-matched controls, the
prevalence of MetS and 10-year cardiovascular risk were compared.
Treatment with antipsychotics was associated with a signiﬁcantly
worse metabolic proﬁle than controls (P < 0.0001), and MetS was
more prevalent (P¼ 0.001), as was a high CVD risk across a number
of outcomes. This was consistent across diagnostic categories.123idence: The relationship between psychiatric disease and metabolic
i.org/10.1016/j.tmsr.2018.04.003
G. Ferns / Translational Metabolic Syndrome Research xxx (2018) 1e16 11Metabolic abnormalities in patients with BD may be secondary
to obesity, aspects of the disorder itself, or its treatment. A
comparison was made with respect to IR, features of the MetS and
serum adiponectin levels in a group of overweight BD patients
taking sodium valproate and a group of non-psychiatric control
subjects matched for age, gender, BMI and ethnicity. Adiponectin
is a hormone derived from adipose tissue that modulates glucose
and fatty acid oxidation.124 The frequency of the MetS was high in
both groups (50% and 32%, respectively), although this was not
signiﬁcantly different between groups (p ¼ 0.06). Similar fre-
quencies of insulin resistance (HOMA-IR), abdominal obesity,
hypertriglyceridaemia, hypertension and fasting hyperglycaemia
were found in both groups. High-density lipoprotein cholesterol
levels were lower in patients (p ¼ 0.006). Serum adiponectin
concentrations were unexpectedly found to be higher in the BD
patients compared to the control subjects. The frequencies of
insulin resistance [deﬁned using HOMA-insulin resistance (IR)],
MetS and its individual components were not signiﬁcantly
different in patients taking atypical antipsychotic medication and
patients not on these medications. Frequencies of IR and MetS
were similar in bipolar patients taking sodium valproate and
matched control subjects, but dyslipidaemia was more
frequent.125
The metabolic status among VPA treated BD patients; drug-free
BD patients (BD-F) and healthy controls were investigated in a
Taiwanese population. The cross-sectional study included 119
healthy controls and 77 BD patients diagnosed according to the
DSMIV-TR criteria. VPA treatment was associated with signiﬁcantly
higher plasma insulin, triglyceride, and BMI levels as well as lower
fasting glucose and HDL levels. However, these biochemical indices
did not differ signiﬁcantly between the BD-F and the healthy con-
trol groups. Hence, treatment with VPA may increase the risk of
metabolic disturbances in patients with BD.126
The prevalence of MetS in patients with BD and schizophrenia
patients receiving SGAs were compared Patients treated with SGAs
were closely matched for age, sex, and race. Compared to
schizophrenia patients those with BD had lower BMI, were more
likely to have been treated with mood stabilizers, and less likely to
have been treated with clozapine. Despite these differences, BD
and schizophrenia patients had comparable rates of MetS (43.2%
versus 45.9%, p ¼ 0.71) and predicted CHD events (10-year
risk > 10%: 18.9% versus 23.4%, p ¼ 0.47). Using 100 mg/dL as
the adapted glucose criterion, MetS rates were 54.0% in both pa-
tient groups (p ¼ 1.0). Mood stabilizer co-treatment was not
associated with MetS or its individual criteria. The authors suggest
that these ﬁndings indicate a shared susceptibility to
antipsychotic-related metabolic dysregulation that is not primarily
related to psychiatric diagnosis or concomitant mood stabilizer
treatment.127
Serum leptin, adiponectin and paraoxonase1 (an antioxidant
enzyme present on the HDL particle) levels were investigated in
women receiving pharmacotherapy for various psychiatric disor-
ders. A small study compared 32 obese women who were
receiving treatment for psychiatric disorders, and a control group
of 22 obese females who were free from psychiatric disorders. BMI
and hip circumference were positively related with serum leptin
levels, hip circumference correlated positively with adiponectin
levels, and waist to hip ratio correlated positively with serum
paraoxonase levels. In the control group, BMI as well as waist and
hip circumferences were positively correlated with leptin levels.
Weight, BMI, and hip circumference were also negatively corre-
lated with the adiponectin/leptin ratio in the control group. The
authors concluded that there appears to be a higher risk for
obesity-related disorders in patients treated with psychiatric
drugs.128Please cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://do9.3. Cohort studies
The incidence of MetS was determined for newly diagnosed
patients with MDD (n ¼ 30) and BD (n ¼ 24). At baseline, 11.2% of
patients met diagnostic criteria for MetS and this increased to 16.8%
at follow-up. Women had higher rates of MetS but rates were
similar across diagnoses. In this study, changes in CHD and MetS
risk were not associatedwith a speciﬁc type of pharmacotherapy, as
all medication classes appeared to increase risk.129
The Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) study provided further evidence of the metabolic risk
associated with different atypical antipsychotics. Based on data
from this and other studies, it was concluded that clozapine and
olanzapine treatment can produce substantial changes in weight
and an increased risk of associated metabolic disturbances. Ris-
peridone and quetiapine treatment may produce moderate
changes in mean weight in comparison to treatment with other
atypical antipsychotics. Aripiprazole and ziprasidone treatment
may induce the lowest mean changes in weight gain and has been
reported to have no effect on risk for adverse metabolic changes,
among currently available atypical agents.130
Consecutive patients with FES in India were recruited into a
prospective randomized, double blind controlled study and ran-
domized to receive either, haloperidol, olanzapine or risperidone.
The prevalence of MetS was assessed based on two criteria- ATP IIIA
and IDF criteria. This was comparedwith a gender, age, exercise and
diet matched healthy control group. The prevalence of MetS was
10.1% and 18.2% as assessed by ATP IIIA and IDF criteria respectively.
The prevalence of MetS in patients with schizophrenia was at least
ﬁve times higher than for a matched healthy control group. Olan-
zapine increased the prevalence of MetS to between 20 and 25%,
risperidone to 9e24% and haloperidol to 0e3%.131
Weight gain among inpatients that received antipsychotic drug
therapy was compared in patients treated with ﬁrst and SGA
therapy for one year or longer (risperidone N ¼ 40; olanzapine
N ¼ 30). The control group included 30 patients who were treated
with ﬁrst generation antipsychotics. Following one year of treat-
ment 55% of the patients gained weight, 2% remained at the same
weight and 43% had lost weight. Currently there appears to be no
alternative to personal follow up for each individual patient and
personal treatment plans for medication, diet and physical
exercise.132
HOMA-IR was used in non-diabetic patients with schizophrenia
treated with clozapine or olanzapine. No difference was found
between the groups treated with clozapine and olanzapine with
respect to age, gender, race, BMI, waist circumference (WC), or lipid
levels. Nor did measures of insulin sensitivity differ between the
groups (HOMA-IR, or SI).133
The effects of switching from quetiapine to ziprasidone on
weight, safety, and effectiveness were investigated in 241 subjects
with schizophrenia or schizo-affective disorder who had been
treated with quetiapine (300 mg/day) for 3 months with either
sub-optimal efﬁcacy or poor tolerability. They were enrolled into a
16-week, open-label, ﬂexible-dose trial, with a 16-week follow-up
(total 32 weeks). The primary endpoint was weight change from
baseline at 16 weeks, when there was a small but statistically sig-
niﬁcant reduction in weight, with a mean change from baseline
of 0.73 kg, as well as improved lipid proﬁles, regardless of their
metabolic status and disease severity at baseline.134
Hence there is good evidence that antipsychotic medication can
increase adiposity, and this also suggests that treatment with
antipsychotic medicationsmay be associatedwith an increased risk
for IR, dyslipidaemia, and DM. Different antipsychotic drugs appear
to be associated with different degrees of treatment-induced in-
creases in body weight and adiposity, ranging from modest effectsidence: The relationship between psychiatric disease and metabolic
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Table 5
Impact of speciﬁc antipsychotic drugs on weight gain.
Risk of weight gain Drugs
High Clozapine, Olanzapine, Quetiapine, Zotepine
Moderate Amisulpride, Asenapine, Iloperidone,
Paliperidone, Quetiapine, Risperidone
and Sertindole
Low Aripiprazole, Lurasidone and Ziprasidone
G. Ferns / Translational Metabolic Syndrome Research xxx (2018) 1e1612(<2 kg) with amisulpride, ziprasidone, and aripiprazole to clinically
signiﬁcant increases with olanzapine (4e10 kg). Metabolic changes
in patients who receive antipsychotic agents may contribute to the
development of the MetS.135 Antipsychotic treatment may
contribute to obesity by several potential mechanisms, as previ-
ously discussed.
The high prevalence of MetS in patients with BD is reported to
be comparable to the prevalence of MetS in patients with schizo-
phrenia. A small study has also investigated if the presence of MetS
was associated with hyper-homocysteinaemia in patients with BD
(N ¼ 36) and schizophrenia (N ¼ 46) treated with SGA. The pres-
ence of the MetS was signiﬁcantly associated with an elevated
serum homocysteine in all participants.136
SGAs are increasingly being used to treat childrenwith a variety
of psychiatric illnesses. In a cross-sectional study, Devlin et al.
assessed the association of the methylenetetrahydrofolate reduc-
tase (MTHFR) C677T gene variant with features of MetS in SGA-
treated (n ¼ 105) and SGA-naive (n ¼ 112) children. The MTHFR
C677T variant, is associated with higher concentrations of serum
homocysteine, and was chosen because it was previously reported
to be associated with risk for CVD,137,138 although this is now con-
tended.139 It is also associated with features of MetS in adults
without psychiatric illness. MetS was determined in children, based
on the: waist circumference 90th percentile for age and sex;
plasma triglyceride 1.24 mmol/L; plasma high-density lipopro-
tein-cholesterol 1.03 mmol/L; systolic or diastolic blood pressure
90th percentile for age, sex, and height; and fasting glucose
5.6 mmol/L. 15% of the children treated with SGA had MetS
compared with 2% of the SGA-naive children. The MTHFR 677T
allele was associated (P < 0.05) with MetS (OR 5.75, 95%
CI¼ 1.18e28.12) in the SGA-treated children. A positive relationship
between the MTHFR 677T allele and diastolic blood pressure Z-
scores (P ¼ 0.001) and fasting plasma glucose (P < 0.05) in children
treated with SGAs. There was a high prevalence of MetS in these
children and a metabolic alteration associated with the MTHFR
C677T variant may have a role in the development of MetS features
in children treated with SGAs.140
SGAs are widely used in psychiatric disease and appear to have
different propensities for inducing weight gain. An analysis of the
randomized-controlled trials and observational studies published
between 2010 and 2014 with sample sizes exceeding 100, have
been analysed to determine the ranking of SGAs with respect to
affecting weight gain. Clozapine and olanzapine appear to have the
highest risk, followed by amisulpride, asenapine, iloperidone, pal-
iperidone, quetiapine, risperidone and sertindole in the middle,
and aripiprazole, lurasidone and ziprasidone with the lowest risk.
Younger patients and patients with a lower baseline body mass
index appear to be most vulnerable. The greatest amount of weight
gain occurs within the ﬁrst few weeks of treatment.141
Data were obtained from a longitudinal study initially started in
2007, and included 351 Swiss psychiatric patients, with baseline
metabolic parameters that were monitored at several time-points
(baseline and/or 1, 3, 6, 9, 12 months). IDF and World Health Or-
ganization deﬁnitions were used to deﬁne MetS and obesity,
respectively. The prevalence of MetS and obesity were 22% and 17%,
respectively, at baseline and 32% and 24% after 1 year. ROC analyses
suggested that an early weight gain >5% after a period of 1 month
was the best predictor for longer-term weight gain (15% after 3
months: sensitivity, 67%; speciﬁcity, 88%; 20% after 12 months:
sensitivity, 47%; speciﬁcity, 89%). The authors therefore suggest that
following the prescription of psychotropic drugs, a 5% threshold for
weight gain after 1 month should raise concerns about weight-
controlling strategies.142 This would of course mean an early
follow-up in these patients.Please cite this article in press as: Ferns G, Cause, consequence or coinc
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zapine monotherapy for at least six months and to determine the
most important risk factors associated with the presence of MetS,
was studied in 93 long term hospitalized schizophrenic patients (71
men, 22 women). The prevalence of MetS according to IDF criteria
was 34.4%. Multivariate analysis showed that a family history of DM
(p ¼ 0.002), body mass index >25 kg/m2 (p ¼ 0.002), family history
of dyslipidaemia (p ¼ 0.008), and elevated serum CRP (p ¼ 0.042)
were determinants of MetS. There was a high rate of MetS in pa-
tients treated with olanzapine.143
The relationship between MetS, severity of psychiatric symp-
toms, living arrangements, health behaviour and antipsychotic
medication was investigated in outpatients with schizophrenia
spectrum disorders. A general practitioner and psychiatric nurses
performed a comprehensive health examination for all the patients
with schizophrenia spectrum disorders treated in a psychosis
outpatient clinic MetS was made according to IDF deﬁnition. 276
patients (152 men), the mean age of the group was 44.9 ± 12.6
years. Of the group, 58.7% had MetS. Treatment with clozapine
doubled the risk of MetS (OR¼ 2.04, 95% CI 1.09e3.82, P ¼ 0.03).14410. Managing CVD risk in patients with psychiatric disorders
10.1. Drug treatment
There appear to be signiﬁcant differences in the risks of devel-
oping metabolic abnormalities with the different available SGAs
(see Table 5). This is likely to be due to differential, off-target effects
of these SGGAs on receptors for neurotransmitters that include
central 5-hydroytryptamine-2C and histamine-H1 receptors, and
peripheral M3-muscarinic receptors.145 It may be possible to avoid
these potentially adverse effects by switching to those with the
least metabolic impact. It is also evident that the likelihood of
longer-termweight gain and MetS can be determined within a few
weeks of starting treatment with SGAs. Screening for weight gain
and impaired glucose tolerance would appear to be important, if
longer term CVD risk is to be avoided. This also implies that there
should be a baseline assessment of CVD risk factors. Adherence to
American Psychiatric Association/American Diabetes Association
consensus statement recommendations on rates of baseline lipid
monitoring is disappointingly low in the absence of systems to
encourage or systematise best practice,146 and despite the high
prevalence of CVD risk factors in the populationwith SMI, there are
considerable variations in screening for these risk factors and a
need for improvement in some populations and settings.147
The beneﬁts of treatment with statins in the secondary pre-
vention of CVD are well established,148 although for primary pre-
vention, even in individuals at high-risk, the beneﬁts are contended
with respect to all-cause mortality.149 Psychiatric complications do
not appear to be a prominent feature among the spectrum of re-
ported adverse effects of statins.150 Statins are however, associated
with an increased risk of incident DM and myopathy,148 although
the risk-beneﬁt ratio appears to favour statin use.148 The value of
using statins in low-risk subjects remains debatable.151idence: The relationship between psychiatric disease and metabolic
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patients with SMI, and these co-morbidities increase the risk of
mortality. Given the increased risk of CVD in patients with SMI,
statin use should at least be considered in the primary prevention
of cardiovascular and cerebrovascular events in psychiatric pa-
tients, especially in those at high risk.152 The use of atypical anti-
psychotics and the presence of SMI are now both included in the
QRISK3 algorithm for assessing CVD risk in the United Kingdom.153
Peroxisome Proliferator-Activated Receptors (PPARs) are a
family of nuclear receptors that are involved in nutrient sensing
and whose activation modulate the expression of genes involved in
glucose and lipoprotein metabolism and the inﬂammation path-
ways.154 PPAR agonist, for example the ﬁbrate class of drugs, have
been used for several years in the treatment of metabolic abnor-
malities, such as dyslipidaemia, there has been increasing attention
on their use for inﬂammation-related conditions. In the ﬁeld of
psychiatry, it has recently emerged that inﬂammatory processes are
involved in the pathophysiology of several important disorders,
such as schizophrenia and mood disorders.155 Fibrates are some-
times necessary to treat severe hypertriglyceridaemia, which is
associated with SGA treatment, if an alternative cannot be found.156
10.2. Life style interventions
A sedentary lifestyle is an independent predictor of cardiovas-
cular disease.157 Van Camfort et al. investigated the associations
between sitting time (as a proxy for a sedentary lifestyle), physical
ﬁtness and metabolic parameters in 219 patients with BD. A higher
BMI, poorer physical ﬁtness and higher dose of antipsychotic
medication were independent predictors of higher levels of sitting
behaviour. The model explained 76.5% of the variability in the
sitting time.158 Interventions that target a sedentary lifestyle are
probably necessary in patients with SMI, including BD. Eskilinen
et al. have reported that self-reported regular physical activity
decreased the risk of MetS signiﬁcantly.144
In a meta-analysis of 26 studies that examined the impact of
lifestyle interventions on CVD risk factors, Fernandez-San-Martin
and colleagues have reported a signiﬁcant improvement in
anthropometric (BMI and waist circumference) and biochemical
parameters (fasting blood glucose, and fasting triglycerides and
total cholesterol) at 3 months that were maintained at 12
months.159 Some of the practical difﬁculties of introducing a com-
bined intervention of diet and physical activity are described by
Masa-Font and colleagues160 in the CAPiCOR trial of men with
schizophrenia. This suggests that long term compliance is neces-
sary for any signiﬁcant impact on CVD risk factors. In their sys-
tematic review of dietary interventions, Teasdale and colleagues
report that dietician-led and early interventions appeared to have
the greatest impact on weight control.
161The role and importance of the intestinal microbiota in hu-
man health is now being better understood.162 Recent studies have
reported a strong impact of antipsychotics on intestinal microbiota
composition,163 and this may have an impact on adiposity.164
Experimental models suggest that treatment with prebiotics may
be effective in limiting weight gain following treatment with
antipsychotics.165
11. Conclusions
MetS is a common constellation of cardiovascular risk factors. Its
prevalence appears to be higher among some groups of patients
with psychiatric disease, such as schizophrenia and BD, and this
may, in part, account for the increased morbidity and mortality in
these patients. The relationship between SMI and MetS is complex.
SMI may cause a predisposition to MetS; features of MetS, such asPlease cite this article in press as: Ferns G, Cause, consequence or coinc
syndrome, Translational Metabolic Syndrome Research (2018), https://doobesity, may exacerbate SMI, and there are likely to be common risk
factors that contribute to both conditions. Treatment with anti-
psychotics and anti-depressive drugs may increase the risk of MetS
even further. This may be due to off-target effects of these drugs,
including effects on appetite, weight gain, and sedentariness. The
impact on weight gain appears to occur within weeks, and weight
gain during this time may be predictive of much greater weight
gain in the longer term. Despite the very high risk of CVD in pa-
tients with psychiatric disease, physical screening for MetS and
weight gain after commencing treatment with SGA appears to be
sub-optimal in most settings. Lifestyle interventions, such as
increasing physical activity and dietary change clearly have an
important part to play in reducing the risk of MetS in patients with
SMI, and need to be implemented at an early stage.
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